224 related articles for article (PubMed ID: 27857023)
21. Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.
Quintanal-Villalonga Á; Carranza-Carranza A; Meléndez R; Ferrer I; Molina-Pinelo S; Paz-Ares L
Clin Lung Cancer; 2017 Nov; 18(6):667-674.e1. PubMed ID: 28583379
[TBL] [Abstract][Full Text] [Related]
22. Role of fibroblast growth factor 4 in the growth and metastasis of colorectal cancer.
Ye Y; Jiang D; Li J; Han C; Wang X; Wang F; Li J
Int J Oncol; 2020 Jun; 56(6):1565-1573. PubMed ID: 32236572
[TBL] [Abstract][Full Text] [Related]
23. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor.
Frullanti E; Berking C; Harbeck N; Jézéquel P; Haugen A; Mawrin C; Parise O; Sasaki H; Tsuchiya N; Dragani TA
Eur J Cancer Prev; 2011 Jul; 20(4):340-7. PubMed ID: 21412156
[TBL] [Abstract][Full Text] [Related]
24. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.
da Costa Andrade VC; Parise O; Hors CP; de Melo Martins PC; Silva AP; Garicochea B
Exp Mol Pathol; 2007 Feb; 82(1):53-7. PubMed ID: 17084840
[TBL] [Abstract][Full Text] [Related]
25. Gender-Specific Association Between FGFR4 Gly388Arg Gene Variants and Hypertension.
Al-Daghri NM; Mohammed AK; Al-Attas OS; Draz HM; Alokail MS
Genet Test Mol Biomarkers; 2017 Jul; 21(7):422-427. PubMed ID: 28650667
[TBL] [Abstract][Full Text] [Related]
26. FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.
Peláez-García A; Barderas R; Torres S; Hernández-Varas P; Teixidó J; Bonilla F; de Herreros AG; Casal JI
PLoS One; 2013; 8(5):e63695. PubMed ID: 23696849
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients.
Shen YY; Lu YC; Shen DP; Liu YJ; Su XY; Zhu GS; Yin XL; Ni XZ
World J Gastroenterol; 2013 Jul; 19(28):4568-75. PubMed ID: 23901234
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
Hu L; Cong L
Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
[TBL] [Abstract][Full Text] [Related]
29. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
[TBL] [Abstract][Full Text] [Related]
31. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
32. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression.
Stadler CR; Knyazev P; Bange J; Ullrich A
Cell Signal; 2006 Jun; 18(6):783-94. PubMed ID: 16109476
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor receptor 4 as a potential prognostic and therapeutic marker in colorectal cancer.
Li CS; Zhang SX; Liu HJ; Shi YL; Li LP; Guo XB; Zhang ZH
Biomarkers; 2014 Feb; 19(1):81-5. PubMed ID: 24410190
[TBL] [Abstract][Full Text] [Related]
34. FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
Bai YP; Shang K; Chen H; Ding F; Wang Z; Liang C; Xu Y; Sun MH; Li YY
Cancer Sci; 2015 Oct; 106(10):1278-87. PubMed ID: 26183471
[TBL] [Abstract][Full Text] [Related]
35. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
[TBL] [Abstract][Full Text] [Related]
36. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Hyytiäinen M; Kilpinen S; Kallioniemi O; Ingvarsen S; Engelholm LH; Taipale J; Alitalo K; Keski-Oja J; Lehti K
Cancer Res; 2010 Oct; 70(20):7851-61. PubMed ID: 20876804
[TBL] [Abstract][Full Text] [Related]
38. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.
Sahadevan K; Darby S; Leung HY; Mathers ME; Robson CN; Gnanapragasam VJ
J Pathol; 2007 Sep; 213(1):82-90. PubMed ID: 17607666
[TBL] [Abstract][Full Text] [Related]
39. Is FGFR4 Gly388Arg missense variant a suitable prognostic marker in neuroblastoma?
Katarzyna S
J Cancer Res Ther; 2023; 19(2):355-358. PubMed ID: 37006072
[TBL] [Abstract][Full Text] [Related]
40. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
